Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Jan 08
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Biotech Industry Analysis
UpdatedJan 17, 2025
DataAggregated Company Financials
Companies117
- 7D-2.1%
- 3M-6.2%
- 1Y25.5%
- YTD1.8%
Over the last 7 days, the Biotech industry has dropped 2.1%, driven by Celltrion declining 1.9%. In the past year, the industry has gained 25%. Looking forward, earnings are forecast to grow by 83% annually.
Industry Valuation and Performance
Has the South Korean Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 17 Jan 2025 | ₩93.1t | ₩10.5t | -₩1,004,347,149,181.00 | 24.5x | -92.7x | 8.9x |
| Sun, 15 Dec 2024 | ₩94.2t | ₩10.5t | -₩1,002,002,014,281.00 | 23.9x | -94x | 9x |
| Tue, 12 Nov 2024 | ₩97.2t | ₩10.3t | -₩650,692,798,177.00 | 26.6x | -149.4x | 9.4x |
| Thu, 10 Oct 2024 | ₩95.4t | ₩10.3t | -₩653,791,712,887.00 | 25.4x | -145.9x | 9.2x |
| Sat, 07 Sep 2024 | ₩89.1t | ₩10.3t | -₩664,461,088,267.00 | 24.1x | -134x | 8.6x |
| Mon, 05 Aug 2024 | ₩90.3t | ₩9.9t | -₩651,620,427,048.00 | 22.7x | -138.6x | 9.2x |
| Wed, 03 Jul 2024 | ₩84.0t | ₩9.9t | -₩651,620,427,048.00 | 22.1x | -128.9x | 8.5x |
| Fri, 31 May 2024 | ₩78.1t | ₩9.9t | -₩643,765,772,388.00 | 20.5x | -121.4x | 7.9x |
| Sun, 28 Apr 2024 | ₩78.6t | ₩9.6t | -₩574,854,220,678.00 | 21.8x | -136.7x | 8.2x |
| Tue, 26 Mar 2024 | ₩85.8t | ₩9.6t | -₩603,302,771,467.00 | 45.5x | -142.2x | 9x |
| Thu, 22 Feb 2024 | ₩74.5t | ₩9.7t | -₩534,696,541,747.00 | 61.7x | -139.3x | 7.6x |
| Sat, 20 Jan 2024 | ₩72.8t | ₩9.7t | -₩537,261,689,777.00 | 61.3x | -135.5x | 7.5x |
| Mon, 18 Dec 2023 | ₩58.9t | ₩10.1t | -₩311,749,314,637.00 | 28.3x | -188.8x | 5.8x |
| Wed, 15 Nov 2023 | ₩55.4t | ₩10.2t | -₩233,197,853,989.00 | 30.6x | -237.4x | 5.4x |
| Fri, 13 Oct 2023 | ₩55.7t | ₩10.2t | -₩239,053,318,689.00 | 28.1x | -233.2x | 5.5x |
| Sun, 10 Sep 2023 | ₩58.8t | ₩10.2t | -₩340,060,706,949.00 | 34x | -172.9x | 5.8x |
| Tue, 08 Aug 2023 | ₩57.8t | ₩10.3t | -₩151,534,704,579.00 | 28.8x | -381.4x | 5.6x |
| Thu, 06 Jul 2023 | ₩57.3t | ₩10.3t | -₩151,534,704,579.00 | 27.5x | -378.1x | 5.6x |
| Sat, 03 Jun 2023 | ₩64.1t | ₩10.3t | -₩151,338,675,579.00 | 32.2x | -423.5x | 6.2x |
| Mon, 01 May 2023 | ₩60.0t | ₩11.0t | ₩317.9b | 24.4x | 188.8x | 5.5x |
| Wed, 29 Mar 2023 | ₩56.5t | ₩10.8t | ₩436.1b | 23.4x | 129.5x | 5.2x |
| Fri, 24 Feb 2023 | ₩57.8t | ₩11.3t | ₩968.6b | 25.4x | 59.6x | 5.1x |
| Sun, 22 Jan 2023 | ₩58.7t | ₩11.3t | ₩751.0b | 24.1x | 78.1x | 5.2x |
| Tue, 20 Dec 2022 | ₩61.8t | ₩10.8t | ₩197.3b | 26.6x | 313x | 5.7x |
| Thu, 17 Nov 2022 | ₩63.7t | ₩10.8t | ₩342.4b | 21.6x | 186x | 5.9x |
| Sat, 15 Oct 2022 | ₩57.2t | ₩10.8t | ₩348.0b | 20.4x | 164.4x | 5.3x |
| Mon, 12 Sep 2022 | ₩64.8t | ₩10.8t | ₩495.4b | 23.8x | 130.9x | 6x |
| Wed, 10 Aug 2022 | ₩74.9t | ₩10.7t | ₩597.6b | 26.4x | 125.2x | 7x |
| Fri, 08 Jul 2022 | ₩69.2t | ₩10.7t | ₩597.6b | 24x | 115.7x | 6.5x |
| Sun, 05 Jun 2022 | ₩68.2t | ₩10.6t | ₩622.0b | 27.8x | 109.7x | 6.4x |
| Tue, 03 May 2022 | ₩70.9t | ₩10.0t | ₩866.3b | 27.4x | 81.9x | 7.1x |
| Thu, 31 Mar 2022 | ₩76.6t | ₩9.9t | ₩867.7b | 29.4x | 88.3x | 7.7x |
| Sat, 26 Feb 2022 | ₩68.1t | ₩9.4t | ₩783.3b | 31.9x | 87x | 7.3x |
| Mon, 24 Jan 2022 | ₩79.0t | ₩9.4t | ₩787.4b | 33.8x | 100.4x | 8.4x |
Price to Earnings Ratio
100.4x
Current Industry PE
- Investors are optimistic on the South Korean Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 8.9x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 3.7% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | 0.14% | |
| Healthcare | -0.48% | |
| Biotech | -2.12% | |
| Biotech | -2.12% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A950160 Kolon TissueGene | ₩30.50k | 6.6% +₩151.2b | 165.0% | n/a | |
| A214450 PharmaResearch | ₩263.50k | 5.0% +₩129.9b | 124.8% | PE30.8x | |
| A298380 ABL Bio | ₩32.50k | 4.7% +₩70.0b | 53.3% | PS48.5x | |
| A347850 D&D Pharmatech | ₩57.00k | 5.8% +₩32.8b | n/a | PS73.6x | |
| A115180 Qurient | ₩5.53k | 15.8% +₩26.8b | 30.1% | PS22.4x |
